Dr. Mui’s laboratory studies the mechanism by which negative regulators like IL10 inhibit target cells in order to intervene therapeutically during deregulated immune responses. Her group has identified an agonist of the inositol phosphatase SHIP, which mimics the anti-inflammatory action of IL10. Her laboratory confirmed that the agonist inhibits inflammation in animal models of septicemia and colitis – both diseases resulting from over-enthusiastic activation of the immune system. The agonist has now been licensed to a spin-off company for clinical development for the treatment of human inflammatory disease. The Mui lab is now characterizing small molecule SHIP inhibitors which might be used to reverse pathogen-induced immunosuppression. Work is also continuing towards characterizing other signalling pathways utilized by IL10 and other negative immune cell regulators.